Literature DB >> 19068499

Effects of hypertension and hypercholesterolemia on cognitive functioning in patients with alzheimer disease.

Felicia C Goldstein1, Angela V Ashley, Yohannes W Endeshaw, John Hanfelt, James J Lah, Allan I Levey.   

Abstract

This study investigated the relationship between the vascular comorbidities (VCs) of hypertension and hypercholesterolemia and the cognitive phenotype of Alzheimer disease (AD). Seventy-four AD patients underwent objective measurement of blood pressure and serum cholesterol levels, and they received a detailed neuropsychologic evaluation examining attention, memory, language, visuomotor/visuospatial skills, and executive functioning. Multiple regression analyses controlling for demographic variables, overall cognitive status, and the presence of diabetes/cardiac disease indicated that an increase in the number of VCs, but not their severity, was associated with poorer verbal and visual recall, visuoconstructive and spatial analysis, verbal reasoning, and set shifting. The findings demonstrate that VCs are associated with specific aspects of cognitive functioning in AD patients. The mechanisms likely involve the effects of VCs on cerebrovascular disease including white matter disruption. The results highlight the importance of controlling these risk factors in patients who carry the diagnosis of AD.

Entities:  

Mesh:

Year:  2008        PMID: 19068499      PMCID: PMC2634658          DOI: 10.1097/wad.0b013e318188e80d

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  53 in total

1.  Serum cholesterol levels are associated with impaired recall memory among older people.

Authors:  Jian Zhang; Robert E McKeown; Ihab Hajjar
Journal:  Age Ageing       Date:  2005-03       Impact factor: 10.668

2.  Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease.

Authors:  Kina Höglund; Steinar Syversen; Piotr Lewczuk; Anders Wallin; Jens Wiltfang; Kaj Blennow
Journal:  Exp Brain Res       Date:  2005-06-04       Impact factor: 1.972

3.  Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT).

Authors:  D Larry Sparks; Suzana Petanceska; Marwan Sabbagh; Donald Connor; Holly Soares; Charles Adler; Jean Lopez; Chuck Ziolkowski; Jeff Lochhead; Patrick Browne
Journal:  Curr Alzheimer Res       Date:  2005-12       Impact factor: 3.498

4.  Population-based study of medical comorbidity in early dementia and "cognitive impairment, no dementia (CIND)": association with functional and cognitive impairment: The Cache County Study.

Authors:  Constantine G Lyketsos; Leslie Toone; JoAnn Tschanz; Peter V Rabins; Martin Steinberg; Chiadi U Onyike; Christopher Corcoran; Maria Norton; Peter Zandi; John C S Breitner; Kathleen Welsh-Bohmer; James Anthony; Truls Østbye; Erin Bigler; Carl Pieper; James Burke; Brenda Plassman; Robert C Green; David C Steffens; Liz Klein; Carol Leslie; Jeannette J Townsend; Bonita W Wyse; Ronald Munger; Michael Williams
Journal:  Am J Geriatr Psychiatry       Date:  2005-08       Impact factor: 4.105

5.  Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study.

Authors:  Kathleen M Hayden; Peter P Zandi; Constantine G Lyketsos; Ara S Khachaturian; Lori A Bastian; Gene Charoonruk; JoAnn T Tschanz; Maria C Norton; Carl F Pieper; Ron G Munger; John C S Breitner; Kathleen A Welsh-Bohmer
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Apr-Jun       Impact factor: 2.703

6.  APOE genotype, vascular risk factors, memory test performance and the five-year risk of vascular cognitive impairment or Alzheimer's disease.

Authors:  Jennifer D Klages; John D Fisk; Kenneth Rockwood
Journal:  Dement Geriatr Cogn Disord       Date:  2005-09-13       Impact factor: 2.959

7.  Effects of age and hypertension status on cognition: the Veterans Affairs Normative Aging Study.

Authors:  Christopher B Brady; Avron Spiro; J Michael Gaziano
Journal:  Neuropsychology       Date:  2005-11       Impact factor: 3.295

8.  Developmental and vascular risk factors for Alzheimer's disease.

Authors:  Amy R Borenstein; Yougui Wu; James A Mortimer; Gerard D Schellenberg; Wayne C McCormick; James D Bowen; Susan McCurry; Eric B Larson
Journal:  Neurobiol Aging       Date:  2005-03       Impact factor: 4.673

9.  Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study.

Authors:  W T Longstreth; Alice M Arnold; Norman J Beauchamp; Teri A Manolio; David Lefkowitz; Charles Jungreis; Calvin H Hirsch; Daniel H O'Leary; Curt D Furberg
Journal:  Stroke       Date:  2004-11-29       Impact factor: 7.914

10.  Hypertension and cognitive performance in African Americans with Alzheimer disease.

Authors:  F C Goldstein; A V Ashley; L J Freedman; L Penix; J J Lah; J Hanfelt; A I Levey
Journal:  Neurology       Date:  2005-03-08       Impact factor: 9.910

View more
  24 in total

1.  An exploration of subgroups of mild cognitive impairment based on cognitive, neuropsychiatric and functional features: analysis of data from the National Alzheimer's Coordinating Center.

Authors:  John J Hanfelt; Joanne Wuu; Ann B Sollinger; Melanie C Greenaway; James J Lah; Allan I Levey; Felicia C Goldstein
Journal:  Am J Geriatr Psychiatry       Date:  2011-11       Impact factor: 4.105

Review 2.  Brain health and shared risk factors for dementia and stroke.

Authors:  Hannah Gardener; Clinton B Wright; Tatjana Rundek; Ralph L Sacco
Journal:  Nat Rev Neurol       Date:  2015-10-20       Impact factor: 42.937

3.  Dysexecutive versus amnestic Alzheimer disease subgroups: analysis of demographic, genetic, and vascular factors.

Authors:  Jesse Mez; Stephanie Cosentino; Adam M Brickman; Edward D Huey; Jennifer J Manly; Richard Mayeux
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Jul-Sep       Impact factor: 2.703

4.  Relationship between late-life hypertension, blood pressure, and Alzheimer's disease.

Authors:  Yuan-Han Yang; Catherine M Roe; John C Morris
Journal:  Am J Alzheimers Dis Other Demen       Date:  2011-09-15       Impact factor: 2.035

5.  Side chain-oxidized oxysterols regulate the brain renin-angiotensin system through a liver X receptor-dependent mechanism.

Authors:  Laura Mateos; Muhammad-Al-Mustafa Ismail; Francisco-Javier Gil-Bea; Rebecca Schüle; Ludger Schöls; Maura Heverin; Ronnie Folkesson; Ingemar Björkhem; Angel Cedazo-Mínguez
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

6.  Dietary cholesterol degrades rabbit long term memory for discrimination learning but facilitates acquisition of discrimination reversal.

Authors:  Bernard G Schreurs; Carrie A Smith-Bell; Desheng Wang; Lauren B Burhans
Journal:  Neurobiol Learn Mem       Date:  2013-09-25       Impact factor: 2.877

7.  Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease.

Authors:  Christiane Reitz; Ming-Xin Tang; Nicole Schupf; Jennifer J Manly; Richard Mayeux; José A Luchsinger
Journal:  Arch Neurol       Date:  2010-12

8.  The impact of vascular comorbidities on qualitative error analysis of executive impairment in Alzheimer's disease.

Authors:  Melissa Lamar; David J Libon; Angela V Ashley; James J Lah; Allan I Levey; Felicia C Goldstein
Journal:  J Int Neuropsychol Soc       Date:  2009-10-19       Impact factor: 2.892

9.  [Effects of long-term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study)].

Authors:  Jürgen Schrader; Stephan Lüders; Hans-Christoph Diener; Hermann Haller; Roland E Schmieder; Klaus Wahle; Wenefrieda Smolka; Claudia Jung; Kurt Bestehorn
Journal:  Med Klin (Munich)       Date:  2008-07-15

Review 10.  ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease.

Authors:  Yohei Shibuya; Catherine Cy Chang; Ta-Yuan Chang
Journal:  Future Med Chem       Date:  2015-12-15       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.